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Abstract
Background: To address the lack of standard terminology to describe extracellular RNA (exRNA) data/metadata, we have
launched an inter-community effort to extend the Gene Ontology (GO) with subcellular structure concepts relevant to
the exRNA domain. By extending GO in this manner, the exRNA data/metadata will be more easily annotated and
queried because it will be based on a shared set of terms and relationships relevant to extracellular research.
Methods: By following a consensus-building process, we have worked with several academic societies/consortia,
including ERCC, ISEV, and ASEMV, to identify and approve a set of exRNA and extracellular vesicle-related terms and
relationships that have been incorporated into GO. In addition, we have initiated an ongoing process of extractions of
gene product annotations associated with these terms from Vesiclepedia and ExoCarta, conversion of the extracted
annotations to Gene Association File (GAF) format for batch submission to GO, and curation of the submitted annotations
by the GO Consortium. As a use case, we have incorporated some of the GO terms into annotations of samples from the
exRNA Atlas and implemented a faceted search interface based on such annotations.
Results: We have added 7 new terms and modified 9 existing terms (along with their synonyms and relationships) to
GO. Additionally, 18,695 unique coding gene products (mRNAs and proteins) and 963 unique non-coding gene products
(ncRNAs) which are associated with the terms: “extracellular vesicle”, “extracellular exosome”, “apoptotic body”, and
“microvesicle” were extracted from ExoCarta and Vesiclepedia. These annotations are currently being processed for
submission to GO.
Conclusions: As an inter-community effort, we have made a substantial update to GO in the exRNA context. We have
also demonstrated the utility of some of the new GO terms for sample annotation and metadata search.
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Background
Extracellular RNAs (exRNAs) are broadly defined as
RNAs that are present in the acellular portions of bio-
fluids, such as body fluids (blood, cerebrospinal fluid,
bile, lymph, vitreous humour, amniotic fluid, ascites,
pleural, pericardial and peritoneal fluids, etc.), secretions
(saliva, urine, sweat, tears, milk, seminal fluid, etc.), and
cell and tissue culture supernatants. RNA sequencing
analyses of exRNAs demonstrate that they represent al-
most the entire range of cellular RNA species, including
rRNAs, tRNAs, mRNAs, miRNAs, piRNAs, lncRNAs,
and circular RNAs ([1–5]). However, the profiles of cel-
lular and exRNAs are not identical, as some cellular
RNAs appear to be highly enriched in the exRNA frac-
tion, while others appear to be significantly underrepre-
sented, and still others lie between these extremes of
enrichment or exclusion.
Among the many reasons cells might release exRNAs,
perhaps the most intriguing possibility is that exRNAs
might contribute to intercellular communication. Export
of exRNAs may also be used to eliminate undesired
RNAs from the originating cell. Finally, some exRNAs
might be generated in a nonspecific manner, either by
living cells (e.g. by a ‘bulk flow’ process) or as a conse-
quence of cell death (reviewed in [6]).
ExRNAs appear to be universally associated with carrier
vehicles, likely due to the rapid degradation of unpro-
tected RNAs in biofluids ([4, 7–10]). The biochemical
properties of these carriers are likely to be the primary de-
terminant of the types and specific identities of exRNAs
that are secreted from cells, as well as their stability in the
extracellular milieu. The first exRNA carriers identified
were RNA viruses, which carry not only viral RNAs, but
also varying levels of host-encoded RNAs. For example,
retroviruses typically carry two host tRNAs and sub-
stoichiometric levels of host mRNAs from the cell in
addition to two copies of the viral RNA genome and key
viral proteins ([11–16]). In fact, retrovirally infected cells
produce more “empty” virus-like particles (VLPs) than in-
fectious virions. These VLPs have failed to encapsulate the
viral RNA genome, but can carry as much as 10 kb of
host-encoded RNA ([17]). More recently, it has been dis-
covered that virally uninfected cells also release RNAs into
the extracellular space, and that these exRNAs are associ-
ated with extracellular vesicles (EVs), lipoproteins (LPPs,
most commonly HDLs ([10, 18]), LDLs ([18, 19])), and
ribonucleoprotein particles (RNPs, most commonly
Ago2-containing RNPs ([9, 20]). While the biogenic
mechanisms underlying the release of exRNA-containing
EVs, LPPs, and RNPs are still being investigated, it is clear
that they are not generated by a mechanism that is com-
mon to all of them.
Evidence for EVs and exRNA was first provided more
than seventy-five years ago by Albert Claude’s observation
that uninfected chick and mammalian cells release RNA-
containing vesicles ([21]). However, these non-viral EVs
remained largely uninvestigated for decades. EVs re-
entered the literature in the late 1960’s with descriptions
of calcifying matrix vesicles released by chondrocytes
([22]) and vesicular ‘dust’ released by platelets ([23]).
These and other such vesicles are now commonly referred
to as ‘exosomes’, a term coined by Trams et al. in 1981
([24]) to refer to secreted vesicles that “may serve a
physiologic function”, including both small vesicles of
~100 nm in diameter, and larger vesicles of ~600 nm
diameter or greater.
This first definition of the term ‘exosome’ has been
subsequently overlooked at least twice, first in 1987 by
investigators studying the vesicular secretion of the
transferrin receptor, who adopted a more restrictive def-
inition of the term, conflating it with a delayed mode of
vesicle secretion in which the vesicles bud at endosome
membranes to create a multivesicular body (MVB),
followed later by MVB fusion with the plasma mem-
brane to release the vesicles into the extracellular space
([25]). In 1997, investigators studying an RNA-degrading
protein complex adopted the term ‘exosome’, this time
for an entirely unrelated intracellular biochemical entity
([26]). Not surprisingly, other investigators have come to
different conclusions about which definition holds scien-
tific precedent, resulting in variable use of the term ‘exo-
some’ in different laboratories. EV-related nomenclatures
are further complicated by the common use of additional
terms for secreted vesicles that are variably associated with
different biophysical properties or biogenesis pathways, as
wells as terms based on the cell type or tissue of origin.
The former include ‘ectosomes’ (which refer to EVs that
are produced by budding from the plasma membrane
([27, 28]) and ‘microvesicles’ (which are frequently oper-
ationally defined as EVs that pellet at moderate centrifuga-
tion speeds (~10,000–20,000 xg) [29]), while the latter
include ‘prostasomes’ ([30]), ‘epididymosomes’ ([31]),
‘immunosomes’ ([32, 33]), ‘oncosomes’ ([34]), and ‘platelet
dust’ ([23]). There are even some vesicle names that refer
to observed biological activities (e.g. ‘tolerosomes’ ([35])
and ‘calcifying matrix vesicles’ ([22]).
The International Society for Extracellular Vesicles
(ISEV) has previously attempted to clarify the nomencla-
ture in this field. Its primary achievements have been to
(1) introduce the term ‘extracellular vesicle (EV)’ as a
general term intended to encompass all secreted vesicles,
and encourage its broad acceptance, and (2) encourage
the use of broad-definition terms until a more compre-
hensive understanding of the biogenesis and molecular
compositions of different types of vesicles is developed.
Given the inconsistent vesicle nomenclatures prior to
these ISEV efforts, these were major advances. However,
some inconsistencies still persist. For example, some
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investigators use the term ‘microvesicle’ for larger EVs
(>200 nm diameter) and ‘exosome’ for smaller EVs
(~30–200 nm diameter), while other investigators reject
these size-based definitions and adopt a set of biogenic
definitions in which ‘microvesicle’ describes vesicles that
bud from the plasma membrane while ‘exosome’ de-
scribes vesicles that bud into endosomes and are se-
creted only later upon MVB fusion with the plasma
membrane.
Therefore, investigators are currently forced to make a
choice between these competing definitions, the first be-
ing practical but mechanistically barren, while the latter
being impractical but mechanistically appealing. Unfor-
tunately, there is as yet no unambiguous way to distin-
guish between vesicles that bud from the plasma
membrane versus those that bud at the endosome mem-
brane based on either biophysical properties or molecu-
lar content. This lack of standard nomenclatures creates
i) a problem for individual researchers to annotate/share
their data in an unambiguous manner and ii) a barrier to
productive interactions with the broader research com-
munity, most prominently the biomedical, genomics,
and computational biology communities. To address
such issues, we initiated our metadata standard efforts
within the Metadata Working Group (MWG) of the
Extracellular RNA Communication Consortium (ERCC)
funded by the National Institutes of Health (NIH). As
part of these efforts, MWG matched metadata terms to
existing biomedical ontologies and identified the
exRNA-relevant terms that were absent from major on-
tologies such as the Gene Ontology (GO).
Use of ontologies in metadata annotation
As described in [36], the MWG of the ERCC has devel-
oped the data and metadata standards for annotating
exRNA profiling data for submission to the Data Man-
agement and Resource Repository (DMRR) of the ERCC.
Particularly, a process has been established to submit ex-
periment data to DMRR along with metadata in stand-
ard machine-readable formats (using Linked Data
technologies). The standards cover metadata about do-
nors, biosamples, experiments, studies, and analysis
steps. Such metadata enable targeted selection of sam-
ples of interest (e.g. specific health condition of the
donor, biofluid or cell/tissue type, library preparation
method, and sequencing assay) for integrative analyses.
The metadata also helps organize the data for efficient
interactive as well as programmatic access (e.g. REST
Application Programming Interfaces (APIs)).
The MWG identified existing biomedical ontologies
accessible through the NCBO BioPortal [37] as a source
of commonly accepted terms for annotating exRNA
datasets. Such ontology-based metadata annotation does
not only allow semantic retrieval/query of data in ERCC
data sources, it also allows DMRR data to be integrated
with other data sources with metadata annotated using
the same ontologies. For ontologies to be useful for bio-
logical applications, it is critical that the relevant ontol-
ogies contain meaningful and broadly accepted terms, as
well as ensuring that the relationships between the in-
cluded terms be both accurate and accepted by the per-
tinent scientific community. For an ontology such as
GO which is frequently used for functional enrichment
analysis of genomic datasets, it is also important that
terms be associated with specific gene products (coding
and non-coding RNAs and proteins) in an empirically
supported manner.
The Gene Ontology (GO) Consortium (GOC; http://
www.geneontology.org) is a community-based bioinfor-
matics effort. This Consortium develops, maintains and
extends two interconnected resources: the Gene Ontol-
ogy itself, and a database of GO annotations that associ-
ate specific gene products with concepts in the Gene
Ontology. As of March 2016, there are >42,000 GO
terms for describing concepts relevant to gene product
function in a species-independent manner, providing not
only comprehensive coverage of biological concepts but
also community-wide agreement on how those should
be used to describe gene functions across all organisms.
The GO is organized into three aspects [38]: these are
graph structures comprised of classes for molecular
functions, the biological processes these contribute to,
the cellular locations where these occur (cellular compo-
nents), and the relationships connecting these classes. A
‘GO annotation’ describes the association between a
gene product and an ontology class, as well as references
to the evidence supporting the association. In most
cases, a GO annotation is a statement about gene func-
tion, but because the GO cellular component aspect de-
scribes a “cellular and subcellular anatomy” it can have
broader applications beyond the originally specified GO
annotation usage of “where a gene product is active.”
Thus an association of an exRNA to a cellular component
term does not necessarily imply a function per se, though
a functional role may of course later be discovered.
The GOC continuously provides enhancements to the
ontology and annotation database, as well as its tools
and policies, ensuring that the ontology and annotations
are consistent, and accurately reflect the current state of
biological knowledge.
In recent years, the GO has expanded the number and
type of relationships used to connect terms within the
ontology as well as between GO and other ontologies. A
version of GO containing all relationships, including in-
formation from the Uber anatomy ontology (UBERON)
[39], the Chemical Entities of Biological Interest ontol-
ogy (ChEBI) [40], the Plant Ontology for plant struc-
ture/stage (PO) [41], the Phenotypic Quality Ontology
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(PATO) [42], and the Sequence Ontology (SO) [43], is
called go-plus and is available at http://geneontolo-
gy.org/page/download-ontology. The GOC also makes
other versions of the ontology available at this site.
Methods
As mentioned above, when we initiated our metadata ef-
forts, there was a significant gap between the needs of the
exRNA community and the terms and relationships present
in GO. At that time, the only relevant terms in the Cellular
Component branch were: ‘extracellular vesicular exosome’
(GO:0070062) and ‘prominosome’ (GO:0071914), neither
of which was widely used in the exRNA community. In
addition to lacking the most commonly used terms for
extracellular vesicles, this version of GO lacked terms spe-
cific for exRNA-containing ‘Lipoprotein Particles’ (LPPs)
and ‘Ribonucleoprotein Particles’ (RNPs).
Defining exRNA-related terms based on community
consensus
Our goal was to extend the cellular component branch
of GO to incorporate relevant and empirically supported
terms and relationships that would be useful to and
broadly accepted in the exRNA field, while both main-
taining the internal consistency of GO and leveraging
the knowledge previously encoded in the GO. Initially
focusing on the major area of controversy (vesicles), we
surveyed the literature for relevant references and
sought input from domain experts, including the leader-
ship of the International Society for Extracellular
Vesicles (ISEV), the American Society for Exosomes and
Microvesicles (ASEMV), and the ERCC. This process re-
sulted in three alternative proposals, which ranged from
inclusion of only the most general of terms, to inclusion
of both general and moderately specific terms, to add-
itional inclusion of highly specific terms (Fig. 1). As
shown in Fig. 1, boxes represent GO terms, ovals repre-
sent synonyms, and lines connecting boxes represent the
‘is-a’ relationship (a dashed line connecting a box and an
oval corresponds to a synonymous relationship). The
gray boxes and black lines represent existing terms and
relationships, while the red boxes and red lines represent
the proposed terms and relationships. The option-3 set
of terms/relationships is a subset of the option-2 set
which is a subset of option 1. We then polled the mem-
bership of these societies either during their annual
(ASEMV) or semi-annual (ERC Consortium) meetings
or through an electronic survey (ISEV). The results of
the ISEV poll are shown (Table 1), and are concordant
with the consensuses reached by the other two groups:
Option 2 (set B + set C) is the preferred choice.
We then worked with the GOC team to incorporate
the consensus recommendations, as well as terms rele-
vant to LPPs, as supported by the literature. As part of
the GO update, the GOC editorial team routinely adds
new ontology classes, or modifies existing ones, based
on requests from GO curators or from community ex-
perts. In the latter case, like our case here, changes to
the ontology are proposed using a batch request upon
direct consultation (see [44]).
Adding gene product annotations
The GOC accepts contributions of annotations from ex-
ternal groups, and provides guidance in the ‘Documenta-
tion’ section of its website (http://geneontology.org). The
‘Documentation’ section includes details of the recom-
mended file format, called GAF (Gene Association For-
mat). Annotations submitted to the GOC undergo
automated checks, followed by manual review by GO
curators, in this case from the Protein Function Content
team at EMBL-EBI.
As sources of gene product annotations in the exRNA
context, ExoCarta [45] and Vesiclepedia [46] are online
databases that catalogue proteins, RNAs and lipids iden-
tified specifically in exosomes and other extracellular
vesicle types, respectively. Recently, ExoCarta was up-
dated with ISEV minimal experimental requirements
feature for definition of extracellular vesicles. In collab-
oration with the GOC editorial team, we have mapped
the ExoCarta and Vesiclepedia gene products (coding
and non-coding RNAs and proteins) onto their corre-
sponding RNAcentral (http://www.rnacentral.org) and
UniProt (http://www.uniprot.org/) identifiers using the
newly extended GO Cellular Component terms.
Incorporating new GO terms into exRNA Atlas as a use
case
The exRNA Atlas is a central data repository developed
and maintained by the DMRR that distributes data pro-
vided by the ERCC. The first public release of the
exRNA Atlas, in early 2016, contained exRNA-seq pro-
files of over 500 samples generated by ERCC members
analyzed uniformly using standard in-house analysis
pipelines and quality-controlled using standards agreed
by the Consortium. The exRNA Atlas browser enables
efficient searching and sub-selection of exRNA profiles
for retrieval and integrative analysis. To facilitate inte-
gration of the datasets into the exRNA Atlas, data and
metadata standards have been developed by the Meta-
data Working Group of the ERCC. The metadata stan-
dards build on metadata data models we previously
developed during the course of the NIH Epigenome
Roadmap project, International Human Epigenome Con-
sortium (IHEC) project, and in collaboration with the
ENCODE3 project, and NCBI. The metadata include
core objects such as biosamples, donors, experimental
protocols, studies and analysis methods. The Genbor-
eeKB document modeling system was used to define
Cheung et al. Journal of Biomedical Semantics  (2016) 7:19 Page 4 of 9
syntactic and semantic models for ontology-rich multi-
faceted metadata based on the lightweight JSON syntax.
The latest release of the exRNA Metadata Standard as-
sociates various biomedical ontologies to both the attri-
bute (key) values as well as with the attributes themselves
and supports dynamic validation against ontologies avail-
able in NCBO Bioportal. More than twenty data elements
within the metadata model are associated with ontologies,
such as biofluids, disease types, anatomical locations, cell
culture sources, cell lines, tissues, and other properties
needed to describe biosamples and donors. A number of
these elements reflect the clinical focus of the ERCC,
defined by ontologies such as the Systematized Nomencla-
ture of Medicine - Clinical Terms (SNOMEDCT) (https://
www.nlm.nih.gov/research/umls/Snomed/snomed_main.h
tml) for biofluid type as well as anatomical location of the
biosamples and Human Disease Ontology (DOID) [47] for
disease types. To effectively identify the source from
which the exRNA is extracted, the new GO terms have
been used to annotate the biosamples deposited in the
exRNA Atlas.
Results and discussions
ExRNA terms and relationships added to GO
Based on the option-2 proposal shown in Fig. 1, the ERCC
group worked with EMBL-EBI members of the GOC edi-
torial team to add the proposed terms (including syno-
nyms) and relationships to GO. Figure 2 shows these
terms (with GO IDs) and relationships in red. Any future
terms added to GO and representing types of vesicles that
are part of the extracellular region will be automatically
classified under GO:1903561 ‘extracellular vesicle’.
Fig. 1 The three different options of extending GO to include ExRNA terms and relationships
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Gene product annotations extracted from ExoCarta and
Vesiclepedia
At the time of writing this manuscript, 18,695 coding
(mRNA and protein) and 963 non-coding (ncRNAs)
gene products (including isoforms) were annotated with
the GO terms: ‘extracellular vesicle’, ‘extracellular exo-
some’, ‘apoptotic body’ and ‘microvesicle’ identified in dif-
ferent species (Table 2) from ExoCarta and Vesiclepedia.
The Protein Function Content team at EMBL-EBI are
currently working on importing annotations from
ExoCarta and Vesiclepedia into the GOC. We believe
that the gene product annotations extracted from these
resources would further aid the scientific community in
downstream cellular component enrichment analysis
leading to understanding the molecular mechanism of
extracellular vesicle biogenesis, as well as sorting and se-
creting under normal and pathophysiological microenvi-
ronments. While granular/specific annotations would be
more informative, ontological inferencing can be applied
to a given term (extracellular vesicle) to automatically
retrieve its annotations and those associated with its
descendant terms (e.g. extracellular exosome). GO query
engines like QuickGO (http://www.ebi.ac.uk/QuickGO/)
support this type of query. We anticipate that updating
the gene products associated with each GO term will be
an ongoing process.
The use of GO terms to annotate exRNA metadata and
implement faceted search within the exRNA Atlas
browser
We have implemented a search interface that allows
users to browse exRNA Atlas biosamples based on
different facets of metadata, including the type of bio-
fluid, cell culture source, disease, and exRNA source.
The facets (categories of ontology concepts) provide
an effective means for navigating/filtering a large set
of exRNA profiles data based on different aspects of
the samples. The metadata terms linked to ontologies
in BioPortal have been augmented to include the
newly defined exRNA terms (Fig. 3). By annotating
Fig. 2 The list of exRNA-related terms, synonyms and relationships that have been added to GO
Table 1 ISEV poll results
Rank 1 2 3 4
Option 1 16 86 89 21
Option 2 162 36 8 6
Option 3 33 83 91 5
Option 4 1 7 24 180
580 ISEV members received the poll, 212 answered it. The first question was
to rank the four options by order of preference. As shown in Fig. 1, the
proposed options were: Option 1 = Set A + B + C; Option 2 = Set B + C; Option
3 = Set C; Option 4 = none of the above. Number of answers for each
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the exRNA sources using these community-agreed
terms and by exposing a new facet (exRNA source)
through the ExRNA browser, we have enabled more
precise biologically meaningful search of the ExRNA
Atlas.
Significance of our results and other possible extensions
These substantial changes to GO reflect the current
state of the exRNA field, representing the current litera-
ture from the perspective of the consensus among three
major professional societies in this field (ISEV, ASEMV,
and ERCC). We believe that the new exRNA-relevant
terms, together with their relationships to each other and
with the existing GO terms, as well as the associated gene
products, will be useful for annotating the increasing num-
ber of manuscripts and datasets being generated by the
exRNA community. We also expect that they will prove
useful for literature mining, data repository integration,
and for computational analysis of exRNA data. Given the
rapid developments in this field, we view the current ver-
sion of the relevant areas of the ontology to be a work in
progress. We anticipate frequent future amendments to
incorporate as well as refine additional terms, relation-
ships, and associated gene products as the community de-
velops a more precise and comprehensive understanding
of the biogenesis, biophysical properties, molecular com-
position, and functions of different types of exRNA-
associated EVs, LPPs, and RNPs. To this end, the ERCC
group aims to continually interrogate the literature and to
solicit input from professional societies and the wider
exRNA community. The ERCC has launched the ExRNA
Portal (exrna.org), a publicly accessible website and com-
munity forum for dissemination of information, sharing of
tools and data (primarily through the ExRNA Atlas), and
aggregation of input. Future proposed amendments will be
posted on the ExRNA Portal and will be subject to a public
Table 2 Summary of the gene product annotations extracted from ExoCarta and Vesiclepedia
GO-Term GO-ID Coding gene products (mRNAs or proteins) Non-coding gene products (ncRNAs)
Extracellular exosome GO:0070062 10,827 953
Apoptotic body GO:0097189 168
Microvesicle GO:1903561 14,668 148
Extracellular vesicle GO:1990742 4029
Total no. of unique coding gene products Total no. of unique non-coding gene products
18,695 963
Fig. 3 The new GO terms have been used to annotate the biosamples deposited in the ExRNA Atlas based on the exRNA Source. The figure is a
screenshot of the faceted search of biosamples in the ExRNA Atlas using the exRNA Source metadata property (facet)
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comment period. As described above, in the metadata as-
sociated with datasets submitted to the ExRNA Atlas, we
permit and request depositors to not only tag datasets with
the appropriate current GO terms, but to also include
more precise keywords, so that over time, frequently used
keywords can be evaluated as possible new GO terms.
In addition, our ExRNA Atlas use case (faceted search)
shows the power of exploiting multiple ontologies in a
sample annotation. For example, our metadata includes a
description of extracellular RNAs isolated from different
types of biofluids. Ontologies such as Uberon [48], Nano-
Particle Ontology [49], SNOMEDCT and Experimental
Factor Ontology [50] contain concepts corresponding to
different types of “Biofluid” (or “Bodily Fluid”). These con-
cepts can be used alongside with the “extracellular space”
concept in GO to describe extracellular RNAs that are iso-
lated from different types of biofluids.
Conclusions
In this manuscript, we have described an inter-community
effort to make a substantial update to GO, focusing on
terms and relationships pertinent to the new field of
exRNA biology. We have demonstrated how these new
GO terms can be used to annotate and search metadata
associated with high-throughput datasets, such as RNAseq
data. In addition, we anticipate that these terms will be
useful as keywords for annotation and querying of the lit-
erature. We have also initiated a systematic, literature-
supported process for associating gene products with each
exRNA-related term, such that they can be used for cellu-
lar component enrichment analysis of omics datasets (e.g.
RNAseq- and gene expression data). We recognize that
fundamental questions regarding the composition, biogen-
esis, and functions of exRNA-containing EVs, lipoproteins,
and ribonucleoprotein complexes remain to be answered.
Therefore, we anticipate that frequent future updates to
GO will be necessary to accurately reflect continued pro-
gress in this rapidly advancing field.
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